Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207504 · ClinicalTrials.gov registry record · Phase 1
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02207504: Completed Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02207504 is a Phase 1 study of Castration-resistant Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 216-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207504, a Phase 1 study of Castration-resistant Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
Primary Outcome
Rate of dose limiting toxicity (DLT) in the first 28 days of study therapy by dose level when escalating doses of crizotinib are combined with enzalutamide and when appropriate a GnRH agonist.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Crizotinib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-08 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 1 |
What the finished NCT02207504 record still lists
NCT02207504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 216-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02207504 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02207504 about?
NCT02207504 is a clinical study titled "Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer". This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT02207504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-08. Estimated completion is 2022-01-03.
What conditions does trial NCT02207504 study?
This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT02207504?
The interventions under investigation include: Enzalutamide (DRUG), Crizotinib (DRUG).
Who is sponsoring clinical trial NCT02207504?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02207504 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02207504's enrollment target sits among peer trials
24 15th of 15 higher than 1 of 15 other Castration-resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Castration-resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RECRUITING · Phase 1
-
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
RECRUITING · Phase 1
-
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia